首页> 外文会议>World biomaterials congress >Gene expression and canonical pathways in experimental frozen-thawed ovarian grafts treated with scaffold-base delivery of adipose tissue-derived stem cells
【24h】

Gene expression and canonical pathways in experimental frozen-thawed ovarian grafts treated with scaffold-base delivery of adipose tissue-derived stem cells

机译:基因表达和典型途径在实验冷冻卵巢移植物中,用脂肪组织衍生的干细胞支配支架碱递送治疗

获取原文

摘要

Introduction: Previous works of our group demonstrated that cellular therapy with adipose tissue-derived stem cells (ASC) in a scaffold-based delivery is better than the directly injection for improve the quality of frozen-thawed ovarian autografts. However, new researchers are necessary to evaluate the gene profile expressed in this graft to ensure that this therapy. Materials and Methods: Twelve 12-week-old adult female Wistar rats were use. Frozen-thawed ovarian grafts of adult female rats were treated with rat ASC delivery in an acellular matrix (Gelfoam) immediately after an autologous retroperitoneal transplant (n=6). Controls received Gelfoam with vehicle (DMEM low glucose, n=6). The ovarian grafts were retrieved 30 days after transplantation. Quantitative gene expression (qPCR) for apoptosis, angiogenesis and inflammatory cytokines (84 genes in each pathway) were evaluated by Real Time-Polymerase Chain Reaction (RT-PCR). All reactions were performed in triplicate and controlled by negative RT (no enzyme) and no-template controls and all gene expression levels were normalized to the mean of the internal genes. A Fold Regulation reference value of -2 and +2 was considered for expression analyses. Further analyses were done by Ingenuity Pathway Analysis (IPAO) software in order to determine the main canoninal pathways and the expression values of the top molecules. Results and Discussion: The top canonical pathways involved were Tweak Signaling (53%), Induction of Apoptosis (43%), Apoptosis Signaling (32%), Death Receptor Signaling (30%) and Hepatic fibrosis (17%). The top diseases and biofunctions envolved were: Organismal Injury and Abnormalities (121 molecules), Cancer (118), Inflammatory Response (108), Connective Tissue Disorders (76) and Tumor Morphology (75). The top tox functions were: Increased Levels of Alkaline Phosphatase (11 molecules), AST (7), ALT (6) and Creatinine (6) and Decreased Levels of Albumin (5). The 10 top molecules up-regulated, in descending order, were HPSE (+16.4 Fold Change), IL21 (+9.9), S1PR1 (+8.4), IL1A(+7.1), HGF (+7), CXCL11 (+6.7), CCL19 (+6.4), CCR3 (+6.2), CCR6 (+5.4) and LTB (+5.1). The 10 top molecules down-regulated, in descending order, were Hrk (-73.2), CASP14 (-71.1), TP73 (-34.1), DFFB (-27.8), DP63 (-26), CIDEB (-25.7), LTA (-23.6), BCL2L11 (-19.8), CD40LG (-18.5) and CIDEA (-17.8). Conclusion: ASC therapy based on scaffold base-delivery strategy in rat ovarian autografts activated canonical pathways mainly involved with apoptosis. New researchers are necessary to evaluate the real benefit of this treatment.
机译:简介:我们组以前的作品表明,与基于支架输送脂肪组织来源的干细胞(ASC)细胞疗法比直接注射改善冻融卵巢自体移植的质量更好。然而,新的研究是必要的,以评估该移植表达的基因谱,以确保这种疗法。材料与方法:12 12周龄的成年雌性Wistar大鼠使用。自体移植后腹膜(N = 6)后,立即冷冻 - 解冻的成年雌性大鼠在无细胞基质(明胶海绵)与大鼠ASC递送治疗的卵巢移植物。对照接受明胶海绵用媒介物(DMEM低葡萄糖,N = 6)。卵巢移植物移植后30天恢复。通过实时聚合酶链式反应(RT-PCR)对细胞凋亡,血管生成和炎性细胞因子(84个基因在每种途径)定量基因表达(qPCR的)进行了评价。所有反应一式三份进行,并通过负RT(无酶)控制,并且无模板对照和所有基因的表达水平标准化至平均内部基因的。的-2到+2的折叠调控参考值被认为是表达分析。进一步分析由独创性途径分析(IPAO)软件以确定主canoninal途径和顶分子的表达值完成的。结果和讨论:涉及的顶部经典途径是TWEAK信令(53%),细胞凋亡(43%)的诱导,细胞凋亡信号(32%),死亡受体信号(30%)和肝纤维化(17%)。 envolved顶部疾病和生物功能是:有机体损伤与异常(121个分子),癌症(118),炎症反应(108),结缔组织疾病(76)和肿瘤形态(75)。顶部的tox功能进行:增加碱性磷酸酶(11个分子)的水平,AST(7),ALT(6)和肌酸酐(6)和白蛋白的水平降低(5)。 10个顶部分子上调,以递减的次序是HPSE(16.4倍数变化),IL-21(9.9),S1PR1(8.4),IL1A(7.1),HGF(7),CXCL11(6.7) ,CCL19(6.4),CCR3(6.2),CCR6(5.4)和LTB(5.1)。 10个分子下调,以递减的次序是HRK(-73.2),CASP14(-71.1),TP73(-34.1),DFFB(-27.8),DP63(-26),CIDEB(-25.7),LTA (-23.6),BCL2L11(-19.8),CD40LG(-18.5)和CIDEA(-17.8)。结论:基于对大鼠卵巢自体移植脚手架基本交付战略ASC治疗激活经典途径主要涉及与细胞凋亡。新的研究是必要的,以评估这种疗法的真正好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号